Floatz logo

11 assets in Undifferentiated Ovarian Carcinoma

Therapeutic assets addressing Undifferentiated Ovarian Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Carboplatin
Undifferentiated Ovarian Carcinoma
National Cancer Institute (NCI)P3BBB (72)
Adriamycin
Undifferentiated Ovarian Carcinoma
National Cancer Institute (NCI)P3BB (71)
Cediranib
Undifferentiated Ovarian Carcinoma
National Cancer Institute (NCI)P3BB (69)
Olaparib
Undifferentiated Ovarian Carcinoma
National Cancer Institute (NCI)P3BB (68)
Nogitecan
Undifferentiated Ovarian Carcinoma
National Cancer Institute (NCI)P2/3BB (66)
Docetaxel
Undifferentiated Ovarian Carcinoma
National Cancer Institute (NCI)P3BB (65)
Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
Undifferentiated Ovarian Carcinoma
Mayo ClinicP2B (59)
Atezolizumab
Undifferentiated Ovarian Carcinoma
National Cancer Institute (NCI)P2/3B (57)
Durvalumab
Undifferentiated Ovarian Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Adavosertib
Undifferentiated Ovarian Carcinoma
National Cancer Institute (NCI)P2CCC (52)
Tolinapant
Undifferentiated Ovarian Carcinoma
National Cancer Institute (NCI)P1/2CC (47)